92 304

Cited 0 times in

Cited 16 times in

Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study

DC Field Value Language
dc.contributor.authorHun, Chang-
dc.contributor.authorHyeon, Gwang-
dc.contributor.authorChoi, Hwa Young-
dc.contributor.authorHan, Sojung-
dc.contributor.authorJang, Eun Sun-
dc.contributor.authorChon, Young Eun-
dc.contributor.authorChang, Young-
dc.contributor.authorKim, Kyung-Ah-
dc.contributor.authorKim, Do Young-
dc.contributor.authorYim, Hyung Joon-
dc.contributor.authorKim, Hye-Li-
dc.contributor.authorJeong, Sook-Hyang-
dc.contributor.authorKim, In Hee-
dc.date.accessioned2024-03-22T05:50:29Z-
dc.date.available2024-03-22T05:50:29Z-
dc.date.created2024-04-03-
dc.date.issued2023-07-
dc.identifier.issn2287-2728-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/198240-
dc.description.abstractBackground/Aims: To eliminate hepatitis B virus (HBV) and hepatitis C virus (HCV) according to the World Health Orga-nization (WHO) criteria in 2021, this study investigated the national core indicators representing the current status of viral hepatitis B and C in South Korea. Methods: We analyzed the incidence, linkage-to-care, treatment, and mortality rates of HBV and HCV infection using the integrated nationwide big data of South Korea. Results: According to data from 2018-2020, the incidence of acute HBV infection in South Korea was 0.71 cases per 100,000 population; tthe linkage-to-care rate was only 39.4%. Among those who need hepatitis B treatment, the treat-ment rate was 67.3%, which was less than 80% reported in the WHO program index. The annual liver-related mortality due to HBV was 18.85 cases per 100,000 population, exceeding the WHO target of four; the most frequent cause of death was liver cancer (54.1%). The annual incidence of newly diagnosed HCV infection was 11.9 cases per 100,000 population, which was higher than the WHO impact target of five. Among HCV-infected patients, the linkage-to-care rate was 65.5% while the treatment rate was 56.8%, which were below the targets of 90% and 80%, respectively. The liver-related annual mortality rate due to HCV infection was 2.02 cases per 100,000 population. Conclusions: Many of the current indicators identified in the Korean population did not satisfy the WHO criteria for validation of viral hepatitis elimination. Hence, a comprehensive national strategy should be urgently developed with continuous monitoring of the targets in South Korea. (Clin Mol Hepatol 2023;29:779-793)-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherKorean Association for the Study of the Liver-
dc.relation.isPartOfCLINICAL AND MOLECULAR HEPATOLOGY-
dc.relation.isPartOfCLINICAL AND MOLECULAR HEPATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleCore indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorHun, Chang-
dc.contributor.googleauthorHyeon, Gwang-
dc.contributor.googleauthorChoi, Hwa Young-
dc.contributor.googleauthorHan, Sojung-
dc.contributor.googleauthorJang, Eun Sun-
dc.contributor.googleauthorChon, Young Eun-
dc.contributor.googleauthorChang, Young-
dc.contributor.googleauthorKim, Kyung-Ah-
dc.contributor.googleauthorKim, Do Young-
dc.contributor.googleauthorYim, Hyung Joon-
dc.contributor.googleauthorKim, Hye-Li-
dc.contributor.googleauthorJeong, Sook-Hyang-
dc.contributor.googleauthorKim, In Hee-
dc.identifier.doi10.3350/cmh.2023.0110-
dc.relation.journalcodeJ00557-
dc.identifier.eissn2287-285X-
dc.identifier.pmid37188331-
dc.subject.keywordHepatitis B-
dc.subject.keywordHepatitis C-
dc.subject.keywordIncidence-
dc.subject.keywordDiagnostic screening programs-
dc.subject.keywordMortality-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.affiliatedAuthorKim, Do Young-
dc.identifier.scopusid2-s2.0-85167849389-
dc.identifier.wosid001042245200006-
dc.citation.volume29-
dc.citation.number3-
dc.citation.startPage779-
dc.citation.endPage793-
dc.identifier.bibliographicCitationCLINICAL AND MOLECULAR HEPATOLOGY, Vol.29(3) : 779-793, 2023-07-
dc.identifier.rimsid82746-
dc.type.rimsART-
dc.description.journalClass1-
dc.description.journalClass1-
dc.subject.keywordAuthorHepatitis B-
dc.subject.keywordAuthorHepatitis C-
dc.subject.keywordAuthorIncidence-
dc.subject.keywordAuthorDiagnostic screening programs-
dc.subject.keywordAuthorMortality-
dc.subject.keywordPlusNATIONAL-HEALTH-
dc.subject.keywordPlusINJECT DRUGS-
dc.subject.keywordPlusHEPATITIS-B-
dc.subject.keywordPlusPEOPLE-
dc.type.docTypeArticle-
dc.identifier.kciidART002976498-
dc.description.isOpenAccessY-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.description.journalRegisteredClasskci-
dc.relation.journalWebOfScienceCategoryGastroenterology & Hepatology-
dc.relation.journalResearchAreaGastroenterology & Hepatology-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.